Literature DB >> 32369002

Ability of quantitative PCR to discriminate Pneumocystis jirovecii pneumonia from colonization.

Thomas Perret1, Antonios Kritikos1, Philippe M Hauser2, Malcolm Guiver3, Alix T Coste2, Katia Jaton2, Frederic Lamoth1,2.   

Abstract

Introduction. Pneumocystis jirovecii pneumonia (PCP) is a severe disease affecting immunocompromised patients. Diagnosis is difficult due to the low sensitivity of direct examination and inability to grow the pathogen in culture. Quantitative PCR in bronchoalveolar lavage fluid (BAL) has high sensitivity, but limited specificity for distinguishing PCP from colonization.Aim. To assess the performance of an in-house quantitative PCR to discriminate between PCP and colonization.Methodology. This was a single-centre retrospective study including all patients with a positive PCR result for P. jirovecii in BAL between 2009 and 2017. Irrespective of PCR results, PCP was defined as the presence of host factors and clinical/radiological criteria consistent with PCP and (i) the presence of asci at direct examination of respiratory sample or (ii) anti-PCP treatment initiated with clinical response and absence of alternative diagnosis. Colonization was considered for cases who did not receive anti-PCP therapy with a favourable outcome or an alternative diagnosis. Cases who did not meet the above mentioned criteria were classified as 'undetermined'.Results. Seventy-one patients with positive P. jirovecii PCR were included (90 % non-HIV patients). Cases were classified as follows: 37 PCP, 22 colonization and 12 undetermined. Quantitative PCR values in BAL were significantly higher in patients with PCP versus colonization or undetermined (P<0.0001). The cut-off of 5×103 copies/ml was able to discriminate PCP cases from colonization with 97 % sensitivity, 82 % specificity, 90 % positive predictive value and 95 % negative predictive value.Conclusions. Our quantitative PCR for P. jirovecii in BAL was reliable to distinguish PCP cases from colonization in this predominantly non-HIV population.

Entities:  

Keywords:  bronchoalveolar lavage fluid; molecular diagnosis; pneumocystosis

Mesh:

Year:  2020        PMID: 32369002     DOI: 10.1099/jmm.0.001190

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  8 in total

1.  Analysis of the influencing factors of the clinical effect of respiratory humidifier in treating AIDS complicated with severe Pneumocystis jiroveci pneumonia.

Authors:  Qi Cao; Wei Zeng; Jingmin Nie; Yongjun Ye; Yanchao Chen
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

2.  Development and Evaluation of Rapid and Accurate CRISPR/Cas13-Based RNA Diagnostics for Pneumocystis jirovecii Pneumonia.

Authors:  Yangqing Zhan; Xiaoqing Gao; Shaoqiang Li; Yeqi Si; Yuanxiang Li; Xu Han; Wenjun Sun; Zhengtu Li; Feng Ye
Journal:  Front Cell Infect Microbiol       Date:  2022-06-15       Impact factor: 6.073

3.  Prognostic factors and clinical efficacy of second-line treatments of Pneumocystis jirovecii pneumonia for non-HIV patients after first-line treatment failure.

Authors:  Anlei Liu; Ruixue Sun; Guanghui Cao; Xiaohang Liu; Huadong Zhu; Jing Yang
Journal:  BMC Infect Dis       Date:  2022-06-14       Impact factor: 3.667

4.  Recognition of Diagnostic Gaps for Laboratory Diagnosis of Fungal Diseases: Expert Opinion from the Fungal Diagnostics Laboratories Consortium (FDLC).

Authors:  Sean X Zhang; N Esther Babady; Kimberly E Hanson; Amanda T Harrington; Paige M K Larkin; Sixto M Leal; Paul M Luethy; Isabella W Martin; Preeti Pancholi; Gary W Procop; Stefan Riedel; Seyedmojtaba Seyedmousavi; Kaede V Sullivan; Thomas J Walsh; Shawn R Lockhart
Journal:  J Clin Microbiol       Date:  2021-06-18       Impact factor: 5.948

5.  Pneumocystis jirovecii Disease: Basis for the Revised EORTC/MSGERC Invasive Fungal Disease Definitions in Individuals Without Human Immunodeficiency Virus.

Authors:  Katrien Lagrou; Sharon Chen; Henry Masur; Claudio Viscoli; Catherine F Decker; Livio Pagano; Andreas H Groll
Journal:  Clin Infect Dis       Date:  2021-03-12       Impact factor: 9.079

6.  Clinical Utilization of DiaSorin Molecular Polymerase Chain Reaction in Pneumocystis Pneumonia.

Authors:  Gregory L Damhorst; Kari J Broder; Elizabeth C Overton; Ronelio Rara; Lindsay M Busch; Eileen M Burd; Andrew S Webster; Colleen S Kraft; Ahmed Babiker
Journal:  Open Forum Infect Dis       Date:  2022-01-10       Impact factor: 3.835

7.  Clinical, Bronchoscopic, and Imaging Findings of e-Cigarette, or Vaping, Product Use-Associated Lung Injury Among Patients Treated at an Academic Medical Center.

Authors:  Scott K Aberegg; Meghan M Cirulis; Sean D Maddock; Andrew Freeman; Lynn M Keenan; Cheryl S Pirozzi; Sanjeev M Raman; Joyce Schroeder; Howard Mann; Sean J Callahan
Journal:  JAMA Netw Open       Date:  2020-11-02

8.  Semiquantitative Real-Time PCR to Distinguish Pneumocystis Pneumonia from Colonization in a Heterogeneous Population of HIV-Negative Immunocompromised Patients.

Authors:  Stine Grønseth; Tormod Rogne; Raisa Hannula; Bjørn Olav Åsvold; Jan Egil Afset; Jan Kristian Damås
Journal:  Microbiol Spectr       Date:  2021-08-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.